- €9.49bn
- €9.62bn
- €1.89bn
Orion falls as it ends painkiller development program
Brief: Orion Terminates Odm-111 Development Program Due To Narrow Therapeutic Window Of The Molecule
Brief: Orion's Partner Bayer Submits Application For Third Indication Of Darolutamide In EU
Finland's Orion eyes US sales boost with blockbuster prostate cancer drug
Brief: Bayer Applies To U.S. FDA For Third Darolutamide Indication, Orion's First Blockbuster
Brief: Orion, Aitia Enter Collaboration In Oncology
Europe Research Roundup: Air France-KLM, Burberry, Wise
Jefferies hikes Orion to 'buy' on better Nubeqa sales forecast
Brief: Orion Provides Positive Data From Darolutamide Studies
Orion slips despite outlook hike, analyst points to likely profit taking
Brief: Orion Upgrades 2024 Outlook
Jefferies ups Orion on strong Nubeqa sales
Europe Research Roundup: Crest Nicholson Holdings, JDE Peet's, L'Oreal
Brief: Orion Expects Gross Profit To Increase, Mostly Driven By Growing Nubeqa Royalties
Brief: Orion Q2 Operating Profit EUR 65.8 Million Vs. Estimate EUR 58.3 Million
Earnings Poll: Orion Oyj second quarter results due on August 8
Bayer eyes wider Nubeqa use on new prostate cancer trial data (updated)
Bayer says darolutamide shown to slow prostate cancer progression
Brief: Orion Says Phase III Aranote Trial Of Darolutamide Meets Primary Endpoint